Cabotegravir (formerly GSK744; GSK1265744; GSK-744; GSK-1265744; Rekambys; Cabenuva) is a potent, orally bioavailable and long-acting inhibitor of HIV integrase approved in 2020 for the treatment and prevention of HIV infection.

Tenofovir Alafenamide hemifumarate (formerly also known as TAF and GS-7340) is a novel prodrug of tenofovir, which is a potent reverse transcriptase inhibitor [nucleotide reverse transcriptase inhibitor (NRTIs)], it is used for the treatment of HIV and Hepatitis B.

Nevirapine (also known as NSC 641530; BI-RG 587; NSC 641530; NVP) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV-1 infection and AIDS.

Tenofovir Alafenamide (formerly also known as TAF and GS-7340) is a novel prodrug of tenofovir, which is a potent reverse transcriptase inhibitor [nucleotide reverse transcriptase inhibitor (NRTIs)], it is used for the treatment of HIV and Hepatitis B.

Ledipasvir (formerly GS5885; GS-5885; trade name Harvoni) is a novel and potent HCV NS5A polymerase inhibitor that is used for the treatment of HCV-hepatitis C virus infection.

Tenofovir hydrate (formerly also known as GS-1278; PMPA; TDF) is an approved anti-HIV drug that blocks reverse transcriptase and hepatitis B virus infections.

RO-0335 is a novel and potent diphenylether nonnucleoside reverse transcriptase inhibitor.

2,2′-Anhydrouridine (Cyclouridine; NSC-157148) is a potent inhibitor of uridine phosphorylase (apparent Ki = 2.268 µM) with anticancer and antiviral effects.

Azvudine (formerly known as FNC; RO-0622; RO0622) is a novel and potent nucleoside reverse transcriptase inhibitor (NRTI) that has been approved in 2021 in China for the treatment of HIV infection. Azvudine also has the potential to be used for the treatment of novel coronavirus pneumonia (COVID-19). On July 25, 2022, Azvudine was conditionally approved […]